Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes

(2014) J. H. Rowe et al.   JOURNAL OF IMMUNOLOGY

Nitric oxide metabolites and arginase I levels in β-thalassemic patients: an Egyptian study

(2012) Samy B. M. El-Hady et al.   ANNALS OF HEMATOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma Indoleamine 2,3-Dioxygenase and Arginase Type I May Contribute to Decreased Blood T-Cell Count in Hemodialysis Patients

(2012) Theodoros Eleftheriadis et al.   RENAL FAILURE

Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer

(2012) Zhi-Jun Jiao   WORLD JOURNAL OF GASTROENTEROLOGY

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma

(2011) Martin Loos et al.   ANNALS OF THORACIC SURGERY

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

(2011) B. Raychaudhuri et al.   NEURO-ONCOLOGY

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

(2010) Xiangli Chen et al.   CANCER BIOLOGY & THERAPY

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

(2010) Isabel Poschke et al.   CANCER RESEARCH

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

(2010) S. Nagaraj et al.   CLINICAL CANCER RESEARCH

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

(2010) Camilla A. Lindqvist et al.   IMMUNOLOGY

PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

(2010) Feng Shi et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression

(2009) S. Mumprecht et al.   BLOOD

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients

(2009) Susanna Mandruzzato et al.   JOURNAL OF IMMUNOLOGY

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

(2009) S Mustjoki et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

(2008) D. Ennishi et al.   ANNALS OF ONCOLOGY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma

(2008) S. Kusmartsev et al.   CLINICAL CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

(2008) Jun-ichi Kitagawa et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer

(2007) Stefanie Gross et al.   IMMUNOLOGY LETTERS